中文名：A922500,DGAT-1抑制劑
英文名：A922500
中文別名：DGAT-1 Inhibitor 4a|(1R,2R)-2-[[4-[[(苯基氨基)羰基]氨基][1,1-聯(lián)苯]-4-基]甲?；鵠環(huán)戊烷羧酸
英文別名：959122-11-3|A 922500|A-922500|A922500|DGAT-1 Inhibitor 4a|Cyclopentanecarboxylic acid, 2-((4'-(((phenylamino)carbonyl)amino)(1,1'-biphenyl)-4-yl)carbonyl)-, (1R,2R)-|44698M475X|(1R,2R)-2-(4'-(3-phenylureido)-[1,1'-biphenyl]-4-carbonyl)cyclopentane-1-carbo
純度：98%
貨號：A129800
包裝：10mg、50mg、5mg
Cas號：959122-11-3
存儲溫度：-20°C儲存
產(chǎn)品介紹：
產(chǎn)品介紹：
DGAT-1 inhibitor A?922500 (A-922500) reduces serum triglyceride levels from baseline at all doses tested; however, this is only statistically significant at the 3?mg/kg dose, which lowers serum triglycerides by 53%. Similarly, the 3?mg/kg dose of A?922500 significantly reduces serum FFA concentrations by 55% and total cholesterol by 25%. DGAT-1 inhibition has no significant effect on body weight at any dose tested. Although A?922500 dpes not significantly affect LDL-cholesterol or HDL-cholesterol individually, the serum LDL/HDL-cholesterol ratio is significantly improved by A?922500 at 0.3 and 3?mg/kg. Similar to the dyslipidemic hamster, treatment with 3?mg/kg A?922500 significantly reduces serum triglyceride concentrations (39%). FFA levels significantly increase over the 14-day period in vehicle-treated animals. This increase is inhibited in a?dose-dependent manner by A?922500 such that FFA concentrations are 32% lower after 14 days of treatment with the DGAT-1 inhibitor at 3?mg/kg, compared with the vehicle group (p < 0.05). HDL-cholesterol is significantly increased from baseline levels by A?922500 at 0.3 and 3?mg/kg; however, this is only significantly increased compared with vehicle at the 3?mg/kg dose. Body weight significantly increases over the 2-week period in vehicle-treated rats, and this is not affected by A?922500. LDL-cholesterol is significantly reduced in the vehicle treated group. DGAT-1 inhibition does not further reduce LDL-cholesterol and has no effect on total cholesterol.
產(chǎn)品用途：
A922500 has been used in the inhibition of diacylglycerol acyltransferase (DGAT) in epithelial human breast cancer cell line (MDA-MB-231), digitonin-permeabilized human cancer cells, human myotubes and macrophages.
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應(yīng)頁面：https://www.aladdin-e.com/zh_cn/A129800.html
關(guān)鍵字： DGAT-1 Inhibitor 4a;(1R,2R)-2-[[4-[[(苯基氨基)羰基]氨基][1,1-聯(lián)苯]-4-基]甲?；鵠環(huán)戊烷羧酸;959122-11-3;A 922500
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產(chǎn)和銷售，已陸續(xù)建立多個工廠和研發(fā)中心。作為領(lǐng)軍企業(yè)，阿拉丁始終堅持質(zhì)量第一，連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產(chǎn)品品種超過7萬種，SKU總數(shù)超過46萬，產(chǎn)品線涵蓋了化學(xué)試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個領(lǐng)域，是國內(nèi)少數(shù)化學(xué)試劑到生物試劑全面發(fā)展的國產(chǎn)試劑品牌，產(chǎn)品同步發(fā)布在我們國內(nèi)（www.aladdin-e.com）和海外（www.aladdinsci.com）電商平臺。